This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/company/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/drugbank/
n4http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/patent/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/ontology/mesh/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n19http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n12http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/wikipedia/
n25http://linked.opendata.cz/resource/atc/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00210/identifier/pharmgkb/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00210
rdf:type
n5:Drug
n5:description
Adapalene is a topical retinoid primarily used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. It is currently marketed by Galderma under the trade names Differin in some countries, and Adaferin in India. [Wikipedia]
n5:dosage
n17:271B5C7E-363D-11E5-9242-09173F13E4C5 n17:271B5C7F-363D-11E5-9242-09173F13E4C5 n17:271B5C80-363D-11E5-9242-09173F13E4C5 n17:271B5C81-363D-11E5-9242-09173F13E4C5 n17:271B5C82-363D-11E5-9242-09173F13E4C5 n17:271B5C83-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Rolewski SL: Clinical review: topical retinoids. Dermatol Nurs. 2003 Oct;15(5):447-50, 459-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14619325
n5:group
approved
n5:indication
For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.
n5:manufacturer
n15:271B5C78-363D-11E5-9242-09173F13E4C5 n15:271B5C79-363D-11E5-9242-09173F13E4C5 n15:271B5C76-363D-11E5-9242-09173F13E4C5 n15:271B5C77-363D-11E5-9242-09173F13E4C5 n15:271B5C74-363D-11E5-9242-09173F13E4C5 n15:271B5C75-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00210 n8:DB00210
dcterms:title
Adapalene
adms:identifier
n22:D01112 n23:0299-5910-45 n24:DB00210 n26:31174 n27:54244 n28:Adapalene n29:46505019 n30:PA448047 n31:60164
n5:mechanismOfAction
Mechanistically, adapalene binds to specific retinoic acid nuclear receptors (gamma and beta) and retinoid X receptors but does not bind to the cytosolic receptor protein. Although the exact mode of action of adapalene is unknown, it is suggested that topical adapalene may normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
n5:packager
n15:271B5C6C-363D-11E5-9242-09173F13E4C5 n15:271B5C6D-363D-11E5-9242-09173F13E4C5 n15:271B5C70-363D-11E5-9242-09173F13E4C5 n15:271B5C71-363D-11E5-9242-09173F13E4C5 n15:271B5C6E-363D-11E5-9242-09173F13E4C5 n15:271B5C6F-363D-11E5-9242-09173F13E4C5 n15:271B5C72-363D-11E5-9242-09173F13E4C5 n15:271B5C73-363D-11E5-9242-09173F13E4C5
n5:patent
n7:4717720 n7:7579377
n5:routeOfElimination
Excretion appears to be primarily by the biliary route.
n5:synonym
Adaferin 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid Differine Adapalenum Adapaleno
n5:toxicity
The acute oral toxicity of adapalene in mice and rats is greater than 10 mL/kg. Chronic ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.
n13:hasAHFSCode
n14:84-92-00
n5:synthesisReference
Graziano Castaldi, Pietro Allegrini, Gabriele Razzetti, Mauro Ercoli, "Process for the preparation of adapalene." U.S. Patent US20060229465, issued October 12, 2006.
n9:hasConcept
n10:M0175560
foaf:page
n12:dif1134.shtml n18:adapalene.htm n19:adapalene-cream.html
n5:IUPAC-Name
n6:271B5C88-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5C8E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5C8D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5C8A-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5C8B-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5C8C-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5C86-363D-11E5-9242-09173F13E4C5 n6:271B5C9E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5C84-363D-11E5-9242-09173F13E4C5 n6:271B5C87-363D-11E5-9242-09173F13E4C5 n6:271B5C9F-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5C85-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n25:D10AD03
n5:H-Bond-Acceptor-Count
n6:271B5C94-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5C95-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5C8F-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5C90-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5C92-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5C91-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5C93-363D-11E5-9242-09173F13E4C5
n5:absorption
Absorption of adapalene through human skin is low. Only trace amounts (<0.25 ng/mL) of parent substance have been found in the plasma of acne patients following chronic topical application of adapalene in controlled clinical trials
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
106685-40-9
n5:category
n5:containedIn
n20:271B5C7D-363D-11E5-9242-09173F13E4C5 n20:271B5C7B-363D-11E5-9242-09173F13E4C5 n20:271B5C7C-363D-11E5-9242-09173F13E4C5 n20:271B5C7A-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5C9A-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5C9C-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5C9D-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5C99-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5C98-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5C9B-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5C89-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5C96-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5C97-363D-11E5-9242-09173F13E4C5